PetMed Express is about to give investors and pet parents alike their first real look at how its turnaround plan is holding up.
The company, which operates as PetMeds and is the parent of PetCareRx, announced it will report financial results for its first quarter of fiscal year 2027 on Thursday, August 13, 2026, after market close. Management will host a conference call and webcast at 4:30 p.m. Eastern Time that same day to walk through the results.
How to Tune In
For those looking to follow along live, the call can be accessed by dialing 877-407-0789 within the U.S., or 201-689-8562 internationally. A webcast will also be available for anyone unable to join by phone.
For investors who miss the live session, a replay will be available starting at 7:30 p.m. Eastern Time on the same day and will remain accessible through August 27, 2026. The replay can be reached at 844-512-2921 domestically or 412-317-6671 internationally, using passcode 13761872.
Why This Earnings Report Matters More Than Usual
This isn’t just a routine quarterly check-in. It’s the first update investors will get since PetMed Express closed out a difficult fiscal 2026, a year marked by a widened net loss of $57.3 million, down sharply from a $6.3 million loss the year before, driven in large part by a $26.7 million non-cash goodwill impairment along with inventory write-downs and elevated legal costs.
Despite that steep headline number, the company’s fourth quarter told a slightly more encouraging story: net sales rose sequentially for the first time since fiscal 2024, supported by improvements in prescription medication and auto-ship sales. Management has pointed to that sequential uptick as early evidence that its operational cleanup is starting to gain traction.
A Company That Chose to Stay Independent
This earnings date also lands in the aftermath of a notable corporate decision. PetMed Express’s board previously evaluated two unsolicited cash acquisition proposals, priced between $4.00 and $4.25 per share, before ultimately deciding against pursuing either deal. The board confirmed it will continue operating as an independent, publicly traded company, while noting it remains open to future inbound offers should they arise.
That decision puts extra weight on this upcoming report. Having turned down a buyout, PetMed Express now needs to show shareholders it can deliver sustainable results on its own, built around the cost-cutting and technology upgrades it completed over the past year.
The Turnaround Playbook So Far
Over the past year, PetMed Express has worked through a series of operational fixes aimed at stabilizing the business. That includes remediating previously disclosed material weaknesses in its internal controls, exiting underperforming vendor relationships to capture roughly $6.1 million in annualized savings, and reorganizing staffing across its pharmacy, call center, and distribution operations.
The company has also rolled out new technology infrastructure, including an updated ERP system and a new fraud prevention system, alongside a distribution partnership with Rural King to expand its pet pharmacy services across Rural King’s retail stores and digital platforms.
What to Watch For on August 13
For pet parents who rely on PetMeds for prescription medications and pet health products, and for investors tracking the company’s recovery, this report will offer the clearest signal yet of whether last quarter’s sequential sales improvement was a genuine turning point or a temporary bright spot in an otherwise difficult year.
With a leaner cost structure, new technology in place, and an expanded retail partnership now live, PetMed Express’s first-quarter fiscal 2027 numbers should reveal whether its turnaround strategy is translating into real, sustained momentum.
Pets News Network is India’s first dedicated media platform for the pet and animal industry. For breaking global pet news, brand coverage, and advertising enquiries, contact: ankur@petsnewsnetwork.com
